Bojanic, Nebojsa (55398281100)Nebojsa (55398281100)BojanicBumbasirevic, Uros (36990205400)Uros (36990205400)BumbasirevicBojanic, Gordana (56378889200)Gordana (56378889200)BojanicVukovic, Ivan (23500559400)Ivan (23500559400)VukovicMilojevic, Bogomir (36990126400)Bogomir (36990126400)MilojevicPekmezovic, Tatjana (7003989932)Tatjana (7003989932)Pekmezovic2025-06-122025-06-122017https://doi.org/10.1002/jso.24502https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012253370&doi=10.1002%2fjso.24502&partnerID=40&md5=7acf49bf04d7f5f884604c9cf932f6cfhttps://remedy.med.bg.ac.rs/handle/123456789/7091Background and Objectives: To evaluate the results of testis-sparing surgery (TSS) in patients, with small testicular lesions and a normal contralateral testicle. Methods: In all, 28 patients were treated with TSS for small testicular lesions and a normal contralateral testicle. TSS was considered in patients with testicular lesions smaller than 2 cm and no evidence of metastatic disease. Results: The mean age of patients was 35.3 ± 7.3 years, while the mean diameter of the testicular lesions was 11.4 ± 3.7 mm. After pathological examination, 18 patients (64.3%) were diagnosed with stromal tumors and miscellaneous lesions, while 10 (35.7%) had a germ cell tumor. The median follow-up time for the former group was 33 months and no recurrences were observed. In one patient with germ cell tumor, immediate orchiectomy was performed, while the remaining nine were followed-up (median time, 45 months). One patient developed local recurrence after 39 months. Conclusions: Excellent outcomes for benign lesions could be achieved using TSS. TSS could be offered safely in highly selected patients with germ cell tumors, specifically within a clinical trial but there is more data needed regarding the potential risks and benefits. J. Surg. Oncol. 2017;115:287–290. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.partial orchiectomysmall testicular masstesticular cancer